Colchine for prevention of vascular inflammation in non-cardioembolic stroke (CONVINCE) - a randomised clinical trial of low-dose colchicine for secondary prevention of stroke. Northern Europe extension
Inflammation of the lining of arteries is an important factor contributing to clots, leading to heart attacks and strokes. Current studies are testing medicines traditionally used for inflammation of joints (arthritis) to prevent strokes and heart attacks. CONVINCE is a clinical trial, testing colchicine in low doses, a medicine used for many years to treat gout and other joint disorders. We will compare colchicine to usual care (eg. aspirin, cholesterol lowering medicines and blood pressure treatment) in a randomised fashion.
The trial will take place across Europe in over 100 centres in over 2600 patients over 5 years. This application is to fund the extension of the trial in Northern Europe (Germany, Belgium, Netherlands, Estonia, and Lithuania). The trial has already signficant funding for conduct in Ireland, the UK, Norway, Spain, and Greece, via the HRB Stroke Clinical Trials Network, led by Prof Kelly.
If the trial is 'positive' it will lead to a major step forward in our treatment options for preventing stroke, heart attack, and death in survivors of non-disabling stroke and transient ischaemic attack (mini-strokes).
- Award Date
- 24 February 2017
- Award Value
- Principal Investigator
- Professor Peter J Kelly
- Host Institution
- University College Dublin
- DIFA 2017